Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma

J. F. San Miguel; K. C. Weisel; K. W. Song; M. Delforge; L. Karlin; H. Goldschmidt; P. Moreau; A. Banos; A. Oriol; L. Garderet; M. Cavo; V. Ivanova; A. Alegre; J. Martinez-Lopez; C. Chen; C. Renner; N. J. Bahlis; X. Yu; T. Teasdale; L. Sternas; C. Jacques; M. H. Zaki; M. A. Dimopoulos

doi:10.3324/haematol.2015.125864

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma

Haematologica ◽

10.3324/haematol.2015.125864 ◽

2015 ◽

Vol 100 (10) ◽

pp. 1334-1339 ◽

Cited By ~ 28

Author(s):

J. F. San Miguel ◽

K. C. Weisel ◽

K. W. Song ◽

M. Delforge ◽

L. Karlin ◽

...

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

Prior Treatment ◽

High Dose ◽

Phase 3 ◽

Refractory Multiple Myeloma ◽

High Dose Dexamethasone ◽

Depth Of Response

Get full-text (via PubEx)

Faculty Opinions recommendation of Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718100766.793522195 ◽

2016 ◽

Author(s):

Parameswaran Hari ◽

Binod Dhakal

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

High Dose ◽

Open Label ◽

Phase 3 ◽

Refractory Multiple Myeloma ◽

High Dose Dexamethasone ◽

Open Label Phase

Get full-text (via PubEx)

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70380-2 ◽

2013 ◽

Vol 14 (11) ◽

pp. 1055-1066 ◽

Cited By ~ 454

Author(s):

Jesus San Miguel ◽

Katja Weisel ◽

Philippe Moreau ◽

Martha Lacy ◽

Kevin Song ◽

...

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

High Dose ◽

Open Label ◽

Phase 3 ◽

Refractory Multiple Myeloma ◽

High Dose Dexamethasone ◽

Open Label Phase

Get full-text (via PubEx)

Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma

Haematologica ◽

10.3324/haematol.2014.112557 ◽

2014 ◽

Vol 100 (2) ◽

pp. e63-e67 ◽

Cited By ~ 17

Author(s):

K. W. Song ◽

M. A. Dimopoulos ◽

K. C. Weisel ◽

P. Moreau ◽

A. Palumbo ◽

...

Keyword(s):

Quality Of Life ◽

Multiple Myeloma ◽

Low Dose ◽

High Dose ◽

Health Related Quality ◽

Refractory Multiple Myeloma ◽

High Dose Dexamethasone ◽

Related Quality ◽

Health Related

Get full-text (via PubEx)

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma

Haematologica ◽

10.3324/haematol.2015.137083 ◽

2016 ◽

Vol 101 (7) ◽

pp. 872-878 ◽

Cited By ~ 11

Author(s):

K. C. Weisel ◽

M. A. Dimopoulos ◽

P. Moreau ◽

M. Q. Lacy ◽

K. W. Song ◽

...

Keyword(s):

Multiple Myeloma ◽

Renal Impairment ◽

Low Dose ◽

Phase Iii ◽

High Dose ◽

Refractory Multiple Myeloma ◽

High Dose Dexamethasone ◽

Phase Iii Study

Get full-text (via PubEx)

Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): Overall survival (OS) results of MM-003 after adjustment for crossover.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8593 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8593-8593 ◽

Cited By ~ 1

Author(s):

Gareth J Morgan ◽

Jesus San Miguel ◽

Sujith Dhanasiri ◽

Dawn Lee ◽

Antonio Palumbo ◽

...

Keyword(s):

Multiple Myeloma ◽

Overall Survival ◽

Low Dose ◽

High Dose ◽

Refractory Multiple Myeloma ◽

High Dose Dexamethasone

Get full-text (via PubEx)

Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide

Leukemia & Lymphoma ◽

10.3109/10428191003695660 ◽

2010 ◽

Vol 51 (5) ◽

pp. 937-940 ◽

Cited By ~ 12

Author(s):

Giuseppe Mele ◽

Angela Giannotta ◽

Salvatore Pinna ◽

Giacomo Loseto ◽

Maria Rosaria Coppi ◽

...

Keyword(s):

Multiple Myeloma ◽

Elderly Patients ◽

Frail Elderly ◽

Low Dose ◽

High Dose ◽

Oral Cyclophosphamide ◽

Toxicity Profile ◽

Refractory Multiple Myeloma ◽

High Dose Dexamethasone ◽

Dose Oral

Get full-text (via PubEx)

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

Leukemia & Lymphoma ◽

10.1080/10428194.2020.1747066 ◽

2020 ◽

Vol 61 (8) ◽

pp. 1850-1859

Author(s):

Katja Weisel ◽

Meletios Dimopoulos ◽

Philippe Moreau ◽

Munci Yagci ◽

Alessandra Larocca ◽

...

Keyword(s):

Quality Of Life ◽

Multiple Myeloma ◽

Low Dose ◽

Health Related Quality ◽

Phase 3 ◽

Refractory Multiple Myeloma ◽

Related Quality ◽

Health Related

Get full-text (via PubEx)

S824 A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF ISATUXIMAB, POMALIDOMIDE, AND LOW-DOSE DEXAMETHASONE VS POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

HemaSphere ◽

10.1097/01.hs9.0000561576.58696.ae ◽

2019 ◽

Vol 3 (S1) ◽

pp. 365 ◽

Cited By ~ 4

Author(s):

M. Attal ◽

P.G. Richardson ◽

S.V. Rajkumar ◽

J. San-Miguel ◽

M. Beksac ◽

...

Keyword(s):

Multiple Myeloma ◽

Multicenter Study ◽

Low Dose ◽

Open Label ◽

Phase 3 ◽

Refractory Multiple Myeloma

Get full-text (via PubEx)

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

The Lancet ◽

10.1016/s0140-6736(19)32556-5 ◽

2019 ◽

Vol 394 (10214) ◽

pp. 2096-2107 ◽

Cited By ~ 76

Author(s):

Michel Attal ◽

Paul G Richardson ◽

S Vincent Rajkumar ◽

Jesus San-Miguel ◽

Meral Beksac ◽

...

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

Open Label ◽

Phase 3 ◽

Refractory Multiple Myeloma ◽

Open Label Phase

Get full-text (via PubEx)

Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized, phase 3 KEYNOTE-183 study

Annals of Oncology ◽

10.1093/annonc/mdw375.36 ◽

2016 ◽

Vol 27 ◽

pp. vi324 ◽

Cited By ~ 2

Author(s):

E.M. Ocio ◽

J. Shah ◽

S. Jagannath ◽

M.-V. Mateos ◽

A. Palumbo ◽

...

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

Phase 3 ◽

Refractory Multiple Myeloma

Get full-text (via PubEx)